Q3 EPS Forecast for Tenaya Therapeutics Raised by Analyst

Key Points

• William Blair has raised its Q3 2025 earnings estimate for Tenaya Therapeutics to ($0.15) per share, an improvement from the previous estimate of ($0.28).
• In its latest earnings report, Tenaya Therapeutics reported ($0.14) EPS, exceeding analysts' expectations of ($0.20).
• Over 90% of Tenaya Therapeutics' stock is owned by hedge funds and institutional investors, underscoring strong investor interest in the company.

Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - Investment analysts at William Blair raised their Q3 2025 earnings estimates for Tenaya Therapeutics in a research report issued on Wednesday, August 6th. William Blair analyst S. Corwin now expects that the company will earn ($0.15) per share for the quarter, up from their prior forecast of ($0.28). The consensus estimate for Tenaya Therapeutics' current full-year earnings is ($1.35) per share. William Blair also issued estimates for Tenaya Therapeutics' Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.70) EPS, Q1 2026 earnings at ($0.18) EPS, Q2 2026 earnings at ($0.19) EPS, Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.18) EPS and FY2026 earnings at ($0.73) EPS.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.06.

A number of other equities analysts have also weighed in on TNYA. Chardan Capital restated a "buy" rating and issued a $9.00 price objective on shares of Tenaya Therapeutics in a report on Thursday, August 7th. HC Wainwright reaffirmed a "buy" rating and issued a $5.00 target price on shares of Tenaya Therapeutics in a research report on Friday, April 25th. Finally, Wall Street Zen raised shares of Tenaya Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $6.25.

Tenaya Therapeutics Price Performance

NASDAQ TNYA traded up $0.08 during mid-day trading on Monday, reaching $0.76. The stock had a trading volume of 2,464,804 shares, compared to its average volume of 2,755,070. Tenaya Therapeutics has a 1 year low of $0.36 and a 1 year high of $4.01. The stock has a market cap of $123.38 million, a PE ratio of -0.79 and a beta of 3.01. The company has a fifty day moving average price of $0.67 and a 200 day moving average price of $0.66.

Institutional Investors Weigh In On Tenaya Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Sei Investments Co. bought a new stake in shares of Tenaya Therapeutics during the 4th quarter valued at $100,000. JPMorgan Chase & Co. grew its position in shares of Tenaya Therapeutics by 20,670.3% during the 4th quarter. JPMorgan Chase & Co. now owns 5,155,596 shares of the company's stock valued at $7,373,000 after acquiring an additional 5,130,774 shares during the period. Mariner LLC bought a new stake in shares of Tenaya Therapeutics during the 4th quarter valued at $30,000. Commerce Bank bought a new stake in shares of Tenaya Therapeutics during the 4th quarter valued at $29,000. Finally, Hsbc Holdings PLC bought a new stake in shares of Tenaya Therapeutics during the 4th quarter valued at $45,000. Institutional investors own 90.54% of the company's stock.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.